source
- Pheast Therapeutics sticks with open R&D despite competitor Antengene moving ahead with anti‑CD24 trialsPheast Therapeutics, a Redwood City biotech founded in 2021, builds on Irv Weissman’s 2019 Nature paper that highlighted the CD24 protein as a promising "don’t eat me" target for cancer immunothera…
- FDA expands TEMPO pilot with new digital health partners Limbic, Cadence and DexcomThe FDA is quietly building a pilot program called TEMPO to test a “try first, evaluate later” approach for digital health devices. The agency has added the behavioral‑health firm Limbic to the ro…